Ganetespib Window of Opportunity Study in Head and Neck Cancers

ClinicalTrials.gov ID: NCT02334319

Public ClinicalTrials.gov record NCT02334319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This pilot clinical trial studies how well ganetespib works before surgery in treating patients with stage I-IVA squamous cell carcinoma of the head and neck that can be removed by surgery. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tissue in the laboratory from patients receiving ganetespib may help doctors learn more about the effects of ganetespib on cells. It may also help doctors understand how well patients respond to treatment.

Study identification

NCT ID: NCT02334319
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Emory University; Other
Enrollment: 3 participants

Conditions and interventions

Conditions

Interventions

Ganetespib Drug
Therapeutic Conventional Surgery Procedure
Laboratory Biomarker Analysis Other

Drug · Procedure · Other

Eligibility (public fields only)

Age range: 19 Years to 79 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2014
Primary completion: Jan 31, 2016
Completion: Jan 31, 2016
Last update posted: Jul 25, 2016

2014 – 2016

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Emory University Hospital Midtown	Atlanta	Georgia	30308	—
Emory University/Winship Cancer Institute	Atlanta	Georgia	30322	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02334319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2016 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02334319 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →